IFM Investors Pty Ltd increased its stake in the shares of Thermo Fisher Scientific Inc. (NYSE: TMO – Get a rating) by 19.8% in the first quarter, according to its most recent Form 13F filed with the Securities and Exchange Commission (SEC). The institutional investor owned 61,516 shares of the medical research company after buying an additional 10,164 shares during the quarter. IFM Investors Pty Ltd’s holdings in Thermo Fisher Scientific were worth $36,334,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently increased or reduced their stake in TMO. NewEdge Wealth LLC increased its stake in Thermo Fisher Scientific by 31.1% during the fourth quarter. NewEdge Wealth LLC now owns 910 shares of the medical research company worth $607,000 after buying 216 additional shares in the last quarter. Riverwater Partners LLC bought a new stock position in Thermo Fisher Scientific in Q4 worth $1,440,000. RDA Financial Network increased its stake in shares of Thermo Fisher Scientific by 2.2% in the 4th quarter. RDA Financial Network now owns 2,738 shares of the medical research company valued at $1,827,000 after acquiring 59 additional shares in the last quarter. Geneva Partners LLC increased its stake in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Geneva Partners LLC now owns 5,241 shares of the medical research company valued at $3,497,000 after acquiring 28 additional shares in the last quarter. Finally, CWM LLC bought a new stock position in Thermo Fisher Scientific in Q4 worth $4,477,000. 87.48% of the shares are currently held by institutional investors.
In other news, CEO Marc N. Casper sold 2,181 shares of the company in a trade dated Wednesday, May 4. The stock was sold at an average price of $562.46, for a total value of $1,226,725.26. Following the completion of the sale, the CEO now directly owns 183,373 shares of the company, valued at approximately $103,139,977.58. The sale was disclosed in a document filed with the SEC, accessible via this link. Separately, CEO Marc N. Casper sold 2,181 shares of the company in a trade dated Wednesday, May 4. The shares were sold at an average price of $562.46, for a total value of $1,226,725.26. As a result of the transaction, the CEO now owns 183,373 shares of the company, valued at approximately $103,139,977.58. The sale was disclosed in a legal filing with the SEC, which is available via this hyperlink. Also, COO Michael Lagarde sold 17,150 shares of the company in a transaction dated Tuesday, May 24. The shares were sold at an average price of $548.30, for a total transaction of $9,403,345.00. Following completion of the transaction, the COO now directly owns 15,758 shares of the company, valued at approximately $8,640,111.40. Disclosure of this sale can be found here. Insiders sold a total of 32,361 shares of the company worth $17,992,541 over the past three months. Insiders of the company own 0.43% of the shares of the company.
Thermo Fisher Scientific Stock Performance
Shares of Thermo Fisher Scientific Stock opened at $598.41 on Monday. The company has a current ratio of 1.56, a quick ratio of 1.10 and a debt ratio of 0.77. The company has a 50-day moving average price of $545.16 and a two-hundred-day moving average price of $557.45. Thermo Fisher Scientific Inc. has a 1-year low of $497.83 and a 1-year high of $672.34. The company has a market capitalization of $234.25 billion, a P/E ratio of 31.20, a PEG ratio of 1.93 and a beta of 0.82.
Thermo Fisher Scientific (NYSE: TMO – Get a rating) last released its quarterly results on Thursday, July 28. The medical research company reported earnings per share of $5.51 for the quarter, beating analysts’ consensus estimate of $4.92 by $0.59. The company posted revenue of $10.97 billion in the quarter, versus a consensus estimate of $9.95 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The company’s revenues increased by 18.3% compared to the same quarter last year. During the same period last year, the company posted EPS of $5.60. As a group, analysts expect Thermo Fisher Scientific Inc. to post EPS of 22.63 for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, October 14. Shareholders of record on Thursday, September 15 will receive a dividend of $0.30. The ex-dividend date is Wednesday, September 14. This represents an annualized dividend of $1.20 and a dividend yield of 0.20%. Thermo Fisher Scientific’s dividend payout ratio is currently 6.26%.
Analysts set new price targets
A number of brokerages have recently commented on TMO. SVB Leerink raised its price target on Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an “outperform” rating in a research note on Friday. Morgan Stanley raised its price target on Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered its target price for the stock from $605.00 to $525.00 in a report research on Monday, April 25. Finally, Barclays lowered its price target on Thermo Fisher Scientific from $675.00 to $630.00 and set an “overweight” rating for the company in a Wednesday July 13 research report. One analyst rated the stock with a sell rating, two gave the company a hold rating, twelve gave the company a buy rating and one gave the company a strong buy rating. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $652.79.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life science solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. The Company’s Life Sciences Solutions segment offers reagents, instruments and consumables for biological and medical research, drug and vaccine discovery and production, as well as infection and disease diagnosis for the pharmaceutical, biotech, agricultural, clinical, medical, academic and government markets.
Get news and reviews for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s free daily email newsletter.